

Agenda

10:00am - 11:00am Registration

11:00am - 11:05am Welcome from Mary Clark, CEO, Optimum

11:05am - 11:50am Everything you wanted to know about how to have the best exit to pharma (but were too afraid to ask)

Chair: Nick Bastin, Managing Director, Optimum

- Renée Aguiar-Lucander, CEO, Hansa Biopharma
- Hakan Goker, Managing Director, M Ventures
- Premal Pajwani, Founder and CEO, PRP Advisory
- Peter van de Sande, CEO, Synaffix

11:50am - 12:40pm Who's listening? Tailoring the narrative for maximum punch

Chair: Philip Brainin, Associate, Sound Bioventures

- Amanda Gett-Chaperot, Partner, Kurma Partners
- Bonnie van Wilgenburg, Principal, Monograph Capital
- Mary Clark, CEO, Optimum
- Ray Barlow, CEO, SynOx Therapeutics

12:40pm - 1:40pm Networking lunch

Sponsored by Citi and Nasdaq

1:40pm - 1:45pm Welcome back from Mary Clark, CEO, Optimum

1:45pm - 2:15pm Fireside chat - Biotech, boardrooms, and the occasional billion-dollar exit

Chair: Hannah Kuchler, Global Pharmaceutical Editor, Financial Times

- Antoine Papiernik, Chairman and Managing Partner, Sofinnova Partners

2:15pm - 3:05pm Thriving in the tough times: scaling smart and staying strong

Chair: Kristin-Anne Rutter, Executive Director, Cambridge University Health Partners

- Nicole Mather, Life Sciences Lead, UKI & EMEA, Health Data & AI Lead, UKI, IBM Consulting
- Nick Keher, Chief Financial Officer, Oxford Nanopore Technologies
- Jeremy Skillington, CEO, Poolbeg Pharma

3:05pm - 3:35pm Refreshment break

Sponsored by Babraham Research Campus

- 3:35pm - 3:40pm** Welcome back from Eva Haas, Managing Director, Optimum
- 3:40pm - 4:10pm** Fireside chat - Mind over matter: Ruth McKernan's quest to outsmart dementia (and bureaucracy)
Chair: Dr Daniel Mahony, Senior Partner, Growth Investments, Novo Holdings
• Dr Ruth McKernan CBE, Operating Partner, SV Health Investors
- 4:10pm - 5:00pm** Fever dream or new reality? Taking the temperature of the market and looking ahead to 2026
Chair: Olivia Cavlan, Partner, LifeArc Ventures
• Clarke Futch, Chairman and CEO, HCRx
• Toby Sykes, Managing Director, Life Sciences, ICG
• Gil Bar-Nahum, Managing Director and EMEA Head of Biotechnology, Jefferies
• Victoria Darbyshire, Managing Director, Research Analyst, J.P. Morgan Asset Management
• Søren Møller, Managing Partner, Seed Investments, Novo Holdings
- 5:00pm - 5:10pm** Optimum's featured charity: Brain Tumour Research
• Aimee Clarke, Corporate Partnerships Manager, Brain Tumour Research
- 5:10pm - 5:15pm** Thank you & conclusions from Optimum
- 5:15pm - 7:30pm** Networking reception drinks
Sponsored by Cooley and ICG

Thank you to our sponsors

